AstraZeneca invests C$820 million in Ontario, creating 700 jobs

AstraZeneca is set to invest C$820 million (approximately US$570 million) in Canada to facilitate a move to a larger office in the Greater Toronto Area, creating over 700 high-skilled jobs. This investment aligns with the company's goal of launching 20 new medicines by 2030, having already introduced eight. The Ontario government will support this initiative with a C$16.1 million grant, highlighting the province's aim to establish itself as a leader in life sciences innovation. AstraZeneca has invested over C$1.3 billion in Canada since 2023, contributing significantly to the local economy and research initiatives. AstraZeneca's CEO praised Canada's potential as a hub for life sciences, emphasizing the collaboration with provincial authorities. The investment follows AstraZeneca's recent acquisition of Fusion Pharmaceuticals, further solidifying its commitment to the region's biotechnology sector.